Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 26Lymphoma, Mantle-Cell 18Lymphoma, Large B-Cell, Diffuse 10Lymphoma, Non-Hodgkin 4Lymphoma 4Waldenstrom Macroglobulinemia 3Lymphoma, B-Cell, Marginal Zone 3Leukemia, B-Cell 3Pancreatic Neoplasms 2Leukemia 2Squamous Cell Carcinoma of Head and Neck 1Recurrence 1Pyloric Stenosis, Hypertrophic 1Ovarian Neoplasms 1Neuritis 1Neoplasm, Residual 1Lymphoproliferative Disorders 1Lymphoma, Follicular 1Lymphoma, B-Cell 1Hematologic Neoplasms 1Chromosome 17 deletion 1Carcinoma, Transitional Cell 1Carcinoma, Non-Small-Cell Lung 1Anemia, Hemolytic, Autoimmune 1

Interventions

Cyclophosphamide 9Rituximab 6Tacrolimus 5Busulfan 5fludarabine phosphate 4blinatumomab 4Vincristine 4Prednisone 4Peripheral Blood Stem Cell Transplantation 4Mycophenolic Acid 4Etoposide 4Doxorubicin 4fludarabine 3Whole-Body Irradiation 3Valganciclovir 3Everolimus 3venetoclax 2dacetuzumab 2cobomarsen 2Thiotepa 2Sirolimus 2Patient Reported Outcome Measures 2Methotrexate 2Mesna 2Melphalan 2Filgrastim 2Epoetin Alfa 2Antilymphocyte Serum 2sargramostim 1pomalidomide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Lymphoproliferative Disorders × acalabrutinib × Clear all
NCT04883437 2026-02-09

Acalabrutinib and Obinutuzumab for the Treatment of Previously Untreated Follicular Lymphoma or Other Indolent Non-Hodgkin Lymphomas

Emory University

Phase 2 Recruiting
49 enrolled
Lymphoid

Lymphoma, Follicular, Lymphoproliferative Disorders, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡